ANTIGEN-ANTIBODY COMPLEXES IN BREAST CANCER

本研究的目的是测定可溶性抗原抗体复合物， 乳腺癌患者血清C1 q结合放射免疫分析，Raji 细胞放射免疫测定和（兔）类风湿因子测定。 血清 样本将从乳腺癌患者、纤维囊性乳腺癌患者和乳腺癌患者中获得。 疾病患者和乳腺癌家庭以及适当的健康 控制个人。 将对乳腺癌患者进行纵向随访 用于评价治疗反应，以确定预后 和监测测定的值。 高危人群（纤维囊性乳腺癌） 疾病和乳腺癌家族），以评估 免疫复合物测定的诊断潜力。 抗原-抗体 还将从血清和体液（胸膜）中分离复合物 渗出液）的乳腺癌患者的细胞， 蛋白A亲和层析和使用亲和介质的免疫吸附， IgG的Fc结构域。 此外，分离的免疫复合物将是 在最小变性条件下解离。 解离的抗原是 进行生化和免疫学鉴定。 异源抗血清将 用解离的抗原和分离的复合物以及 将含有表面结合免疫复合物的Raji细胞注射到 兔耐受人IgG，并通过其重组能力进行研究， 解离的抗原并结合恶性乳腺组织。 体外 抗体依赖性细胞介导的细胞毒性，淋巴细胞有丝分裂， 还将进行PHA诱导的淋巴细胞胚细胞生成和LAI测定， 研究抗体-抗原复合物可能的生物学功能。 此外，本发明还 将开发一种放射免疫测定法，可用于早期检测， 监测乳腺癌治疗的疗效。

The objective of this study is to assay soluble antigen-antibody complexes in serum of patients with breast cancer using C1q binding radioimmunoassay, Raji cell radioimmunoassay, and (rabbit) rheumatoid factor assay. The serum specimens will be obtained from breast cancer patients, fibrocystic breast disease patients and breast cancer families as well as from appropriate healthy control individuals. The breast cancer patients will be longitudinally followed for evaluation of the response to treatment in order to determine the prognostic and monitoring values of the assay. The high risk groups (fibrocystic breast disease and breast cancer families) are also to be followed in order to evaluate the diagnostic potential of the immune complex assay. The antigen-antibody complexes are also to be isolated from the serum and body fluids (pleural effusion) of breast cancer patients by molecular exclusion chromatography, protein A affinity chromatography and immunoadsorption using affinity media to the Fc domain of IgG. Further, the isolated immune complexes will be dissociated under the least denaturing conditions. The dissociated antigens are to be characterized biochemically and immunologically. Xenobiotic antisera will be raised with the dissociated antigen(s) and with isolated complexes as well as with the Raji cells containing surface-bound immune complexes injected into rabbits made tolerant to human IgG, and studied by their ability to recombine the dissociated antigen and to bind malignant breast tissues. In vitro antibody-dependent cell-mediated cytotoxicity, lymphocyte mitogenesis, PHA-induced lymphocyte blastogenesis and LAI assays are also to be performed to study the possible biological function of antibody-antigen complexes. Further, a radioimmunoassay will be developed which may be of use in early detection and monitoring of efficacy of therapy for breast cancer.